Publications by authors named "Francesca Maria Rossi"

Claim this Profile
M
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
Filippo Vit, Tamara Bittolo, Antonella Zucchetto, Robel Papotti, Erika Tissino, Ilaria Cattarossi, Francesca Maria Rossi, Marco Rossi

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
Erika Tissino, Annalisa Gaglio, Antonella Nicolò, Federico Pozzo, Tamara Bittolo, Francesca Maria Rossi, Ilaria Cattarossi, Davide Rossi

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Cell Bioenergetic Metabolism Characterizes Chronic Lymphocytic Leukemia Patients with Unfavorable Genetic Factors and with a Better Response to BTK Inhibition.
Simone Mirabilii, Monica Piedimonte, Esmeralda Conte, Daniele Mirabilii, Francesca Maria Rossi

Curr Issues Mol Biol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
Giovanni Del Poeta, Roberta Laureana, Riccardo Bomben, Francesca Maria Rossi, Federico Pozzo, Ilaria Cattarossi

Hematol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Francesca Maria Rossi, Davide Rossi

Am J Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Riccardo Bomben, Francesca Maria Rossi, Filippo Vit, Tamara Bittolo, Antonella Zucchetto

Leukemia· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elastin MIcrofibriL INterfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia.
Erika Tissino, Eliana Pivetta, Alessandra Capuano, Guido Capasso, Riccardo Bomben, Francesca Maria Rossi, Davide Rossi

Hematol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation.
Federico Pozzo, Tamara Bittolo, Erika Tissino, Filippo Vit, Elena Vendramini, Francesca Maria Rossi

Haematologica· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
Giovanni Del Poeta, Riccardo Bomben, Jerry Polesel, Francesca Maria Rossi, Federico Pozzo, Ilaria Cattarossi

Hematol Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.
Riccardo Bomben, Francesca Maria Rossi, Filippo Vit, Tamara Bittolo, Tiziana D'Agaro, Ilaria Cattarossi, Davide Rossi

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Giovanni Del Poeta, Annalisa Biagi, Luca Laurenti, Annalisa Chiarenza, Federico Pozzo, Francesca Maria Rossi

Haematologica· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Francesca Maria Rossi, Davide Rossi

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Francesca Maria Rossi, Davide Rossi

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ.
Monica Brenca, Sabrina Rossi, Erica Lorenzetto, Elena Piccinin, Sara Piccinin, Francesca Maria Rossi

Mol Cancer Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Francesca Maria Rossi, Davide Rossi

Am J Hematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological and clinical implications of mutations in chronic lymphocytic leukemia.
Fary Diop, Riccardo Moia, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Francesca Maria Rossi, Davide Rossi

Haematologica· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Francesca Maria Rossi, Davide Rossi

Eur J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Massimo Gentile, Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Francesca Maria Rossi, Davide Rossi

Leukemia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases.
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Francesca Maria Rossi

Liver Int· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Massimo Gentile, Enrica Antonia Martino, Andrea Visentin, Marta Coscia, Gianluigi Reda, Francesca Maria Rossi

Blood Cancer J· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.
Jared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, Riccardo Bomben, Lodovico Terzi-di-Bergamo, Davide Rossi

Haematologica· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Erika Tissino, Federico Pozzo, Dania Benedetti, Chiara Caldana, Tamara Bittolo, Francesca Maria Rossi, Ilaria Cattarossi, Davide Rossi

Blood· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
Tiziana D'Agaro, Antonella Zucchetto, Filippo Vit, Tamara Bittolo, Erika Tissino, Francesca Maria Rossi

Haematologica· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
Elena Vendramini, Riccardo Bomben, Federico Pozzo, Dania Benedetti, Tamara Bittolo, Francesca Maria Rossi

Leukemia· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media.
Francesco Agostini, Francesca Maria Rossi, Donatella Aldinucci, Monica Battiston, Elisabetta Lombardi

Stem Cell Res Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis